Scilex (SCLX) Holding presented the presentation of post-hoc analysis of the C.L.E.A.R. trial interpreting clinical meaningfulness of safety and efficacy of SP-102 for the treatment of lumbosacral radicular pain, LRP, at the 27th Annual Meeting of American Society of Interventional Pain Physicians, ASIPP, May 15-17, 2025 in Orlando, FL. Interpretation of the clinical meaningfulness of results requires consideration of primary and secondary endpoints assessed with-in subject based on consensus benchmarks, and the between group differences in the context of the overall risk-benefit and in comparison, to other approved products for similar indications. The results of the CLEAR Trial show clear clinically meaningful separation between SP-102 and placebo in multiple with-in subject endpoints.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SCLX:
- Scilex Updates Director Compensation Following Stock Split
- Scilex regains compliance with Nasdaq minimum bid price rule
- Scilex Adjusts Record Date for Preferred Stock Dividend
- Scilex announces change in record date for dividend of preferred stock
- Scilex confirms FDA awards orphan drug designation for colchicine